This site is intended for Healthcare professionals only.
×

Vanta Biosciences arm signs Rs 29 crore deal with Emcure Pharma


Vanta Biosciences arm signs Rs 29 crore deal with Emcure Pharma

The official spokesperson of Emcure Pharmaceuticals Ltd. added, ”Service-efficiency, confidentiality and belief in the team in-charge of execution are important factors for selecting the service providers for carrying out our bio-analytical and bio-equivalence studies and we believe that Vayam has the capabilities.”

New Delhi: Vanta Bioscience Limited has recently announced that its step-down subsidiary ‘Vayam Research Solutions Limited’ has entered into a non-exclusive CRO Service Agreement with Emcure Pharmaceuticals Limited, Pune, for providing services of Bio-Analytical and Bio-Equivalence services to the Company for a period of three years from 2019 to 2022.

The CRO Service Agreement provides for a minimum revenue assurance between Rs. 7.00 crores  Rs.9.00 crores for the financial year 2019-2020 and Rs. 20.00 crores for the financial year 2020-2021.

Also Read: NPPA fixes retail price of Emcure pharma’s HIV drug

Speaking on the development, Mr Dopesh Raja Mulakala, Managing Director, Vanta Bioscience Limited, said, “This deal broadens our horizon. With a steady and assured revenue, we are further encouraged to shorten the timeframe for dominating the category. We now have state—of—the—art facility and world-class expertise to offer services as per global standards.

“We are confident that we will deliver impeccable results and add continuous value to their business. It is a matter of pride to be associated with an established company like Emcure Pharmaceuticals,” Mulakala added.

The official spokesperson of Emcure Pharmaceuticals Ltd. added, ”Service-efficiency, confidentiality and belief in the team in-charge of execution are important factors for selecting the service providers for carrying out our bio-analytical and bio-equivalence studies and we believe that Vayam has the capabilities.”

Also Read: Emcure launches generic Eribulin at 40 percent lower price in India

Spread the love


Source: self
0 comment(s) on Vanta Biosciences arm signs Rs 29 crore deal with Emcure Pharma

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted